CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1

Highlights • Response or non-response as defined by the Choi criteria exhibited the highest predictive value for overall survival compared with the EASL, RECIST 1.1 and mRECIST criteria. • Patients with progression at the first follow-up examination are never downstaged. • Neither tumor necrosis nor tumor hypervascularization were independent predictors of tumor response.